SAT-198 ASC41, a selective THRβ agonist significantly reduces liver fat and ALT in biopsy-confirmed MASH patients after 12-week treatment: an interim analysis of a 52-week serial liver biopsy study

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of Hepatology

Topics

Medicine

Epidemiology

Internal Medicine

Gastroenterology

Hepatology

Show all topics

DOI

10.1016/s0168-8278(24)01768-9